Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.44 |
| ▸ | ESRRG | P62508 | 7/20 | 0.40 |
| ▸ | ESR1 | P03372 | 5/20 | 0.40 |
| ▸ | ESRRB | O95718 | 3/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
| ▸ | ESRRA | P11474 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3550839 | 0.80 | ROCK1 (0.38) | HRH3KCNH2 | |
| Oxalic Acid SCHEMBL3553401 | 0.79 | HRH3 (0.64) | HRH3ESRRGESR1ESRRBKCNH2 | |
| SCHEMBL2560963 | 0.77 | HRH3 (0.70) | HRH3HRH1 | |
| SCHEMBL2563410 | 0.77 | HRH3 (0.70) | HRH3HRH1 | |
| SCHEMBL2563611 | 0.77 | HRH3 (0.70) | HRH3HRH1 | |
| SCHEMBL2560471 | 0.76 | HRH3 (0.72) | HRH3HRH1 | |
| Hydrochloric Acid SCHEMBL3552392 | 0.76 | HRH3 (0.69) | HRH3ESRRGESR1ESRRBKCNH2 | |
| Oxalic Acid SCHEMBL5229363 | 0.75 | HRH3 (0.44) | HRH3ESRRGESR1ESRRBKCNH2 | |
| SCHEMBL2563412 | 0.73 | HRH3 (0.41) | HRH3ESRRGESR1ESRRBKCNH2 | |
| SCHEMBL2563612 | 0.73 | HRH3 (0.41) | HRH3ESRRGESR1ESRRBKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7678807-B2 | Isoquinoline and benzo[H] isoquinoline derivatives, preparation and therapeutic use thereof as antagonists of the histamine H3 receptor | SANOFI-AVENTIS (FR) | 2010-03-16 | — | — | US | disclosed |
| US-20080269199-A1 | ISOQUINOLINE AND BENZO[H]ISOQUINOLINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF AS ANTAGONISTS OF THE HISTAMINE H3 RECEPTOR | SANOFI-AVENTIS (FR) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269199-A1 | ISOQUINOLINE AND BENZO[H]ISOQUINOLINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF AS ANTAGONISTS OF THE HISTAMINE H3 RECEPTOR | HRH3, HRH1, HRH2 | HRH3 1/4885ESRRG 1002/4885ESR1 1085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.